Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulat...( Leading Urologist Presents OrBIT S...),Health

Leading Urologist Presents OrBIT Study Results Comparing Percutaneous Tibial Nerve Stimulation with Pharmaceutical Therapy at the 2008 American

Urological Association Annual Meeting

MINNEAPOLIS, May 21 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, today highlighted results from the OrBIT trial of its Urgent(R) PC System. The Urgent PC System is a proprietary, minimally invasive percutaneous tibial nerve stimulation (PTNS) device designed for office-based treatment of urinary urgency, urinary frequency and urge incontinence, symptoms often associated with overactive bladder (OAB). Dr. Kenneth M. Peters, Chairman of the Department of Urology at Beaumont Hospital in Royal Oak, Michigan, leads the OrBIT (OveRactive Bladder Innovative Therapy) multi-center trial and presented the comparative study's results today at the 2008 American Urological Association (AUA) Annual Meeting, being held in Orlando, Florida.

The results confirm that Urgent PC's PTNS reduces the incidence of voiding episodes at a rate comparable to tolterodine LA, known by the trade name Detrol(R) LA (Pfizer), the leading pharmaceutical therapy for OAB. Highlights from the study include:

-- 80% of PTNS patients considered themselves cured or improved, while 55%

of tolterodine LA patients considered themselves cured or improved.

-- Physicians considered 80% of PTNS patients cured or improved, compared

with 61% of tolterodine LA patients.

-- The frequency of voiding episodes was reduced in 73% of PTNS patients

versus 74% of tolterodine LA patients.

-- No serious adverse events were associated with either treatment. For

PTNS, 18.4% of patients reported at least one adverse event related to

treatment; 24.5% of patients in the tolterodine LA arm
'/>"/>